Johns Hopkins Medicine's Dr. Cole Sterling helps outline the key considerations for treating and living with chronic lymphocytic leukemia (CLL).
Patients facing a chronic lymphocytic leukemia (CLL) diagnosis often encounter complex choices about their next steps in treatment.
Here, Dr. Cole Sterling helps outline the key considerations for treating the disease, including how treatment decisions are made and new developments patients in the D.C. area should be aware of. Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine.
Dr. Cole Sterling
Johns Hopkins Medicine
Watchful waiting is a standard, evidence‑supported approach for many people with early‑stage CLL, allowing patients to avoid unnecessary treatment until the disease shows signs of progression.
Dr. Cole Sterling
Johns Hopkins Medicine
Chronic lymphocytic leukemia (CLL) treatment today is highly individualized, with oncologists and patients working together to choose therapies based on medical factors, lifestyle needs, and personal values.
Dr. Cole Sterling
Johns Hopkins Medicine
The CLL treatment landscape continues to evolve rapidly, with clinical trials exploring next‑generation BTK inhibitors, CAR‑T therapy, bispecific antibodies, and novel combinations—making chemotherapy increasingly rare and expanding options for patients whose treatment stops working.
Sign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.
